Related Experiment Video
Updated: Jul 15, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Selenomethionine suppresses head and neck squamous cell carcinoma progression through TopBP1/ATR and TCAB1 signaling
Bo Zhang1,2, Xiaodong Wei3,4, Jiwu Li5
1Hubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi City, Hubei Province, China. zhboss1234@163.com.
Objective:
Head and neck squamous cell carcinoma (HNSCC) is a histological type of cancer originating from the head and neck. Selenium complexes have been considered as a potential treatment for HNSCC. Therefore, the present work focused on probing the mechanism of L-selenomethionine (SeMet) in HNSCC treatment.
Methods:
MTT and colony formation assays were carried out to analyze the survival rate and proliferation of HNSCC cells, respectively. TUNEL staining was performed to examine apoptosis of HNSCC cells. Additionally, qRT-PCR and Western blotting assays were performed to measure mRNA and protein levels, separately.
Results:
SeMet treatment significantly hindered the survival and promoted the apoptosis of HNSCC cells in a dose- and time-dependently. SeMet administration promoted expression of TopBP1, ATR, H2AX, p-ATR and γ-H2AX, and suppressed that of TCAB1. Importantly, SeMet treatment suppressed the proliferation and facilitated the apoptosis of HNSCC cells, which were partly reversed by down-regulation of TopBP1 or up-regulation of TCAB1. The activation of SeMet to TopBP1/ATR signaling was rescued by TCAB1 up-regulating, and the inhibition of SeMet to TCAB1 expression was rescued by TopBP1 silencing.
Conclusion:
Our findings show that SeMet inhibits the proliferation of HNSCC cells and promotes their apoptosis by targeting TopBP1/ATR and TCAB1 signaling. SeMet is a potential method for HNSCC treatment.
Insights
L-selenomethionine (SeMet) inhibits head and neck squamous cell carcinoma (HNSCC) cell survival and proliferation while promoting apoptosis. This occurs by modulating the TopBP1/ATR and TCAB1 signaling pathways, suggesting SeMet as a potential HNSCC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer.
- Selenium compounds, including L-selenomethionine (SeMet), show promise in cancer therapy.
- Understanding the molecular mechanisms of SeMet in HNSCC is crucial for therapeutic development.
Purpose of the Study:
- To elucidate the mechanism by which L-selenomethionine (SeMet) exerts its anti-cancer effects in head and neck squamous cell carcinoma (HNSCC).
- To investigate the role of TopBP1/ATR and TCAB1 signaling pathways in SeMet-mediated HNSCC treatment.
Main Methods:
- Cell viability and proliferation were assessed using MTT and colony formation assays.
- Apoptosis was evaluated via TUNEL staining.
- Gene and protein expression levels were quantified using qRT-PCR and Western blotting, respectively.
Main Results:
- SeMet significantly reduced HNSCC cell survival and proliferation in a dose- and time-dependent manner.
- SeMet treatment upregulated TopBP1, ATR, H2AX, p-ATR, and γ-H2AX, while downregulating TCAB1.
- The effects of SeMet were partially reversed by manipulating TopBP1 and TCAB1 expression, indicating their critical roles in the observed outcomes.
Conclusions:
- L-selenomethionine (SeMet) effectively inhibits HNSCC proliferation and induces apoptosis.
- The mechanism involves the modulation of TopBP1/ATR signaling activation and TCAB1 expression.
- SeMet represents a potential therapeutic agent for head and neck squamous cell carcinoma.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11:28Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
Published on: May 11, 2016
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...